- Home
- DFIN vs HRMY Comparison
DFIN vs HRMY Comparison
Compare DFIN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFIN
- HRMY
- Stock Information
- Founded
- DFIN 1983
- HRMY 2017
- Country
- DFIN United States
- HRMY United States
- Employees
- DFIN N/A
- HRMY 268
- Industry
- DFIN Other Consumer Services
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- DFIN Consumer Discretionary
- HRMY Health Care
- Exchange
- DFIN Nasdaq
- HRMY Nasdaq
- Market Cap
- DFIN 1.8B
- HRMY 2.1B
- IPO Year
- DFIN N/A
- HRMY 2020
- Fundamental
- Price
- DFIN $54.25
- HRMY $36.87
- Analyst Decision
- DFIN Strong Buy
- HRMY Strong Buy
- Analyst Count
- DFIN 3
- HRMY 9
- Target Price
- DFIN $68.67
- HRMY $55.33
- AVG Volume (30 Days)
- DFIN 312.6K
- HRMY 586.0K
- Earning Date
- DFIN 07-31-2025
- HRMY 08-05-2025
- Dividend Yield
- DFIN N/A
- HRMY N/A
- EPS Growth
- DFIN N/A
- HRMY 58.41
- EPS
- DFIN 2.79
- HRMY 3.10
- Revenue
- DFIN $755,000,000.00
- HRMY $772,527,000.00
- Revenue This Year
- DFIN $1.91
- HRMY $20.45
- Revenue Next Year
- DFIN $4.64
- HRMY $17.32
- P/E Ratio
- DFIN $19.89
- HRMY $11.92
- Revenue Growth
- DFIN N/A
- HRMY 17.74
- 52 Week Low
- DFIN $37.80
- HRMY $26.47
- 52 Week High
- DFIN $70.55
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- DFIN 42.43
- HRMY 61.50
- Support Level
- DFIN $51.18
- HRMY $32.64
- Resistance Level
- DFIN $58.45
- HRMY $36.74
- Average True Range (ATR)
- DFIN 2.61
- HRMY 1.18
- MACD
- DFIN -0.04
- HRMY 0.10
- Stochastic Oscillator
- DFIN 26.94
- HRMY 98.14
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.